ReviewJournal of pharmacy & bioallied sciences2025
Study of Glutathione S-Transferase, Its Isoenzyme (Pi), and Tumor Markers (CA15-3, HE4) in Breast Carcinoma Patients (Before and After Treatment).
Review in Journal of pharmacy & bioallied sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- An integrated in vitro and in silico approach to assess the potential inhibitory actions of auxins on human placental glutathione S-transferase P1-1.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is a leading cause of morbidity and mortality among women globally. Tumor markers play a critical role in diagnosis, treatment monitoring, and prognosis. This review focuses on Glutathione S-transferase (GST), particularly its pi isoenzyme (GSTP1), as well as tumor markers CA15-3 and HE4, in breast cancer patients before and after treatment. These markers are crucial for understanding disease progression, assessing treatment efficacy, and developing therapeutic strategies. Glutathione S-transferase, particularly its pi isoenzyme, along with tumor markers CA15-3 and HE4, holds significant promise in the management of breast cancer. Their combined evaluation before and after treatment could provide crucial insights into disease progression, treatment response, and potential recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.